Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Claudia Duarte to share Foundation's insights on AMR at Leibniz Research Alliance’s Summer School 2024

Claudia Duarte, researcher for the Access to Medicine Foundation’s Antimicrobial Resistance (AMR) Programme, will present a lecture at the Leibniz Research Alliance’s programme on AMR: Navigating between Access & Excess.

Date

25 June 2024

Location

Stechlin, Germany

Date

25 - 27 June 2024

Format

In-person

The Leibniz Research Alliance’s three-day summer school programme on AMR: Navigating between Access & Excess will bring together 30 students from different backgrounds to learn about AMR. More specifically, it will explore the latest efforts in research and development for antibiotics and the implications of AMR from economic, environmental and global policy perspectives. 

On the second day of the programme, Claudia will share findings from the Foundation’s AMR Programme as a guest lecturer in a session called “Where do we stand and what do we need”. During her lecture, she will be sharing insights from the Foundation’s AMR Programme, including findings across three iterations of the AMR Benchmark report, as well as more recent thematic studies that delve into key areas pharmaceutical companies can focus on to help curb drug resistance.

About the Leibniz Research Alliance 

The Leibniz Research Alliance (LRA) INFECTIONS aims to establish an interdisciplinary research agenda to develop new strategies and methods to control spread of pathogens and improve outbreak management by promoting communication across disciplines. 

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

News

Read the latest news about the Access to Medicine Foundation
Featured News

More superbugs, fewer drugs. How can pharma companies ensure the handful of promising antimicrobials make it to the frontlines of drug resistance?

23 May 2024
News

The 2021 AMR Benchmark pinpointed opportunities for companies. Did they take them?

21 November 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved